linjc16/ctgov huggingface dataset:
Changes in Anthropometry Following Ambulatory Orthopaedic Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to study changes in weight, body mass index, and percentage of fat following orthopaedic knee or shoulder surgery.

Official Title
-----------------
Changes in Anthropometry Following Ambulatory Orthopaedic Surgery

Conditions
-----------------
Knee Surgery, Shoulder Surgery

Intervention / Treatment
-----------------
* Device: dual energy X-ray absorptiometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-70 years-old scheduled to undergo knee or shoulder ambulatory surgery Exclusion Criteria: weighs greater than 350 pounds pregnancy history of bariatric surgery dieting or engaged in a weight loss program taking weight loss supplements undergoing other types of surgery during study period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: dual energy X-ray absorptiometry|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fat mass |  | 6-weeks after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lean mass |  | 6-weeks after surgery | 
| Weight |  | 6-weeks after surgery | 
| Body mass index |  | 6-weeks after surgery |
Gynecological Presentations Following Supracervical Hysterectomy

Study Overview
=================
Brief Summary
-----------------
Supracervical hysterectomy is widely common and had many complications either immediate or delayed. In these patients bleeding, infection, chronic pelvic pain are common. In these patients cervical biopsy will be done and histopathological examinations will be done to evaluate the pathology in these patients.

Detailed Description
-----------------
Study design and settings: Cross sectional descriptive studies Patients: 130 patients with hysterectomy recruited at Tanta University Hospital, gynecology clinics in central hospitals in Gharbia governorate will be recruited according inclusion and exclusion criteria. Inclusion criteria include all symptomatizing patients following supracervical hysterectomy, of any age, of any complaints. The Methods: All patients' demographic data, history, indication of hysterectomy, duration since operation, postoperative complications and their main complaint.

Official Title
-----------------
Gynecological Presentations and Pelvic Symptoms Following Supracervical Hysterectomy for Benign Pathologies: A Survey Study

Conditions
-----------------
Gynecological Survey

Intervention / Treatment
-----------------
* Other: Questionanniare


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hysterectomy for benign pathologies Exclusion Criteria: Hysterectomy for malignancy

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| supracervical hysterectomy<br>Patients operated abdominal by removal of uterus, with removal of tubes and ovaries and retaining of cervix | Other: Questionanniare<br>* Filling printed questionnaire + Pelvic examination<br>* Other names: Pelvic examination;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of participant with gynecological symptoms following hysterectomy | Symptoms occurring after hysterectomy | 6 months |
IV Paracetamol Versus IV Dexketoprofen in Dysmenorrhea

Study Overview
=================
Brief Summary
-----------------
Patients presented with dysmenorrhea composed the study population. One gram paracetamol and 50 mg dexketoprofen in 100 ml saline with a rapid infusion were compared in ceasing dysmenorrhea in emergency department.

Detailed Description
-----------------
Patients over 18 years old who presented with dysmenorrhea composed the study population. Patients received pain killer within the last six hours, physical findings consistent with peritoneal irritation, allergy to the study drugs, renal or liver failure, drug addiction, pregnancy or woman with lactation and denied to give inform consent were the exclusion criteria. The pain of the study patients are measured with visual analogue scale at baseline, 15th and 30th minutes. At the end of the 30 minutes, rescue drug need is also recorded.

Official Title
-----------------
Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department

Conditions
-----------------
Dysmenorrhea

Intervention / Treatment
-----------------
* Drug: Paracetamol
* Drug: Dexketoprofen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with dysmenorrhea Patients over 18 years old Exclusion Criteria: denied to give inform consent Renal or liver failure Allergy to the study drugs Receiving pain killer within the last 6 hours. Physical examination findings consistent with peritoneal irritation Pregnancy or patients with lactation Drug addiction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Paracetamol<br>Intravenous 1 gm paracetamol in 100 ml saline with rapid infusion | Drug: Paracetamol<br>* 1 gr paracetamol in 100 ml saline with rapid infusion<br>* Other names: Perfalgan;|
| Active Comparator: Dexketoprofen<br>Intravenous 50 mg dexketoprofen in 100 ml saline with rapid infusion | Drug: Dexketoprofen<br>* 50 mg dexketoprofen in 100 ml saline with rapid infusion<br>* Other names: Arveles;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale | Change in visual analogue scale at 15th minutes from baseline | 15 minutes | 
| Visual Analogue Scale | Change in visual analogue scale at 30th minutes from baseline | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rescue drug need |  | 30 minutes | 
| Adverse effects |  | 30 minutes |
Efficacy of Faviprevir in COVID-19 Treatment

Study Overview
=================
Brief Summary
-----------------
Faviprevir in COVID-19 treatment

Detailed Description
-----------------
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment

Official Title
-----------------
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment

Conditions
-----------------
COVID

Intervention / Treatment
-----------------
* Drug: Favipiravir
* Drug: Chloroquine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with covid 19 Exclusion Criteria: Allergy or contraindications to faviprevir

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Faviprevir<br>Faviprevir | Drug: Favipiravir<br>* Favipiravir<br>* Other names: Faviprevir;|
| Active Comparator: chloroquine<br>chloroquine | Drug: Chloroquine<br>* chloroquine oral tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with mortality or need for mechanical ventilation | Number of patients with mortality or need for mechanical ventilation | 6 months |
Acute Lung Injury After Allogeneic Transplantation - Diagnosis and Early Treatment

Study Overview
=================
Brief Summary
-----------------
Acute lung injury (ALI) is an early complication after allogeneic transplantation causing significant mortality and morbidity. Little is known on early markers and treatment of this complication. Recent data (Hilbert et al.) suggested a beneficial effect of Non-Invasive-Ventilation in ALI-patients immunosuppressed because a many different reasons including stem-cell transplantation. The investigators study is designed to evaluate early markers of ALI after allogeneic transplantation. In case ALI is documented patients are randomized to either conventional therapy (oxygen-support) or conventional therapy plus intermittent Non-Invasive Ventilation. The hypothesis is that Non-Invasive Ventilation improves outcome of ALI after allogeneic transplantation.

Official Title
-----------------
A Randomized Clinical Trial on the Use of Early Intermittent Non-Invasive Ventilation in Patients Suffering From Acute Lung Injury After Allogeneic Transplantation

Conditions
-----------------
Acute Lung Injury

Intervention / Treatment
-----------------
* Other: Intermittent Non-Invasive Ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing allogeneic transplantation presenting with at least two of the following criteria Respiratory rate >25 / min Oxygenation Index <300 Continuous oxygen-saturation <92% whilst breathing room air Exclusion Criteria: Indication for Emergency intubation Hemodynamic instability Left ventricular failure GCS <8 No consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Oxygen<br>Conventional Treatment including Oxygen-support | |
| Experimental: NIV<br>Conventional Treatment plus intermittent Non-Invasive-Ventilation | Other: Intermittent Non-Invasive Ventilation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Lung Injury after allogeneic transplantation
Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary Tumors.

Study Overview
=================
Brief Summary
-----------------
DNA methylation is one of the important ways of protein post-translational modification.Pituitary adenoma (PA) is a benign neuroendocrine tumor that originates from adenohypophysial 45 cells, and accounts for 10%-20% of all primary intracranial tumors. However some PAs can present with high invasiveness and irregular growth, which tend to compresses the optic chiasm and third ventricle, encase the internal carotid artery, and affect hormone secretion from the pituitary gland and hypothalamus. In this study we focus on the mechanism of DNA methylation on the invasiveness of pituitary tumors.

Official Title
-----------------
Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary

Conditions
-----------------
Pituitary Tumors

Intervention / Treatment
-----------------
* Other: no interventions between two groups


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) histologically confirmed PAs, 2) Non-function pituitary adenomas Exclusion Criteria: 1) Associated with other tumors or serious underlying diseases, 2) the medical records were not complete, or the follow-up data were missing.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| invasive PAs<br> | Other: no interventions between two groups<br>* no interventions between two groups<br>|
| non-invasive PAs<br> | Other: no interventions between two groups<br>* no interventions between two groups<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Residual tumor size | Tumor size was evaluated by postoperative MRI | 1 week after surgery | 
| tumor recurrence | During the follow-up, the tumor recurrence was observed closely | three years |
Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Study Overview
=================
Brief Summary
-----------------
The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: Vilazodone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients 18-65 years of age, inclusive.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vilazodone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Study Overview
=================
Brief Summary
-----------------
Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.

Detailed Description
-----------------
This study will use data from an already available cohort of patients enrolled in the Resting study (a project funded by TRANSCAN in 2018) as a training set and data from a new concurrent cohort as validation set.

Official Title
-----------------
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Conditions
-----------------
Non-small Cell Lung Cancer Stage IIIA

Intervention / Treatment
-----------------
* Other: Resected non small cell lung cancer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with an early stage of non small cell lung cancer Indication of surgical resection Patient able to understand and give his consent Patient affiliated to the health insurance Exclusion Criteria: Patient with another cancer in the last 5 years Patient with an allergy to the contrast medium Patient under legal protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Resected early stage non small cell lung cancer<br>Early stage (IA-IIIA) resectable non small cell lung cancer patients receiving surgery | Other: Resected non small cell lung cancer<br>* plasma sample, tissue sample and computed tomography scan images<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Algorithm for disease free survival | Analysis on a training cohort of resected early-stage non small cell lung cancer | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Machine-learning, Resected early stage Non-small Cell Lung Cancer
Effect of Wholegrain Wheat on Body Weight and Composition and Cardiovascular Risk

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the potential beneficial effect of wholegrain on body weight and composition as well as cardiovascular risk in overweight women.

Detailed Description
-----------------
Objective: To study the effect of the 'wholegrain concept', i.e. high intake of wheat wholegrain (WW) vs. refined wheat (RW) grain products on body weight and composition. Design: In this open-labeled randomized trial, 72 postmenopausal women with metabolic syndrome features were prescribed a mild calorie-restricted diet with a deficit of  1,250kJ/d. Following 2 weeks run-in period on RW products, they were randomized to 12 weeks intervention with RW or WW products providing 2,000kJ/d.

Official Title
-----------------
Healthgrain WP 4.4.3: Effects of Whole Grain on Weight Maintenance/Weight Reduction in Overweight Subjects

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: wholegrain
* Other: refined wheat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI 27-37 Postmenopausal (>1y) women 40-70 years old Exclusion Criteria: Medication (hypertensive treatment not included) BP > 160/100 Fasting glucose > 7mM Fasting cholesterol > 6.5mM Smoking Known chronic illnesses

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: WW<br>wholegrain wheat | Other: wholegrain<br>* wholegrain wheat vs. refined wheat products<br>|
| Active Comparator: RW<br>refined wheat | Other: refined wheat<br>* refined wheat products<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight and composition |  | 0, 6 and 12 wks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular risk markers |  | 0, 6 and 12 wks | 
| Fecal parameters |  | 0 and 12 wks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, wholegrain, wheat, cardiovascular disease
Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if use of RNS60 during ACL reconstruction surgery decreases pain and improves functional capacity post-operation.

Official Title
-----------------
Study of RNS60 on Post-operative Pain and Function in Patients Undergoing Knee Anterior Cruciate Reconstruction Surgery

Conditions
-----------------
Anterior Cruciate Ligament Reconstruction

Intervention / Treatment
-----------------
* Drug: RNS60


Participation Criteria
=================

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: RNS60|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of Post-operative pain | Comparison of scores from validated pain scales from post-surgery to one week | 1 week |
PAXIL CR Bioequivalence Study

Study Overview
=================
Brief Summary
-----------------
This study is to determine if controlled release paroxetine tablets manufactured at two different sites behave similarly in healthy volunteers.

Official Title
-----------------
An Open-label, Randomized, Single Dose, Two-period Crossover Study to Demonstrate Bioequivalence Between the Controlled Release Paroxetine Tablet (37.5 mg) Manufactured at Cidra and Mississauga

Conditions
-----------------
Depressive Disorder

Intervention / Treatment
-----------------
* Drug: Paxil CR


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion: Healthy males or females between 18-65. Body weight 50 kg (110 lbs) or higher, and BMI within the range 19-30 kg/m2. Willing to use acceptable forms of birth control throughout the study. Normal labs and ECG. Key Exclusion: Positive test for drugs or alcohol. Positive for Hepatitis or HIV. Any history of psychiatric disorder or suicidal behavior. Has taken another investigational product within 30 days of the start of this study. Has been exposed to more than 4 new chemical entities in the last 12 months. Females who are pregnant or nursing. Regular consumption of alcohol; >14 drinks/week for men or >7 drinks/week for women. Heavy smokers; greater than 20 cigarettes per day.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: open label treatment<br>On each treatment period, subjects will receive controlled release paroxetine 37.5 milligram (mg) on Day 1. | Drug: Paxil CR<br>* Paxil CR 37mg tablet manufactures at two different sites<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Paroxetine blood levels |  | measured up to 168 hours after a single dose. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Additional pharmacokinetic parameters related to blood levels of paroxetine . Safety & tolerability measures including ae reporting & vitals signs & ECGs |  | measured up to 168 hours after a single dose and throughout study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
healthy volunteers, paroxetine